Patient Stories
FILTER BY TESTS
![](/_default_upload_bucket/1609/image-thumb__1609__width800/aaron%20f.0dba1f79.png)
Melanoma diagnosis, now what?
Melanoma is one of the most common cancers found among adults, aged 15-29, in the U.S. and the deadliest if not caught early. There are emerging technologies to help identify a patient’s risk for recurrence and metastasis such as gene expression profiling. Learn about DecisionDX-Melanoma, which is a predictive test to help patients make the most informed treatment decisions.
![](/_default_upload_bucket/1381/image-thumb__1381__width800/Greg%27s%20Story.d68152d8.png)
From Fear to Confidence: DecisionDx-Melanoma. Greg’s Story of Empowerment Over a Melanoma Diagnosis
Discover Greg’s inspiring journey from a cancer diagnosis to a life of outdoor adventures, empowered by the DecisionDx-Melanoma test. Follow his path to knowledge and resilience in the face of melanoma.
![Click to play "Be Your Own Advocate: Morgan England, Stage III Melanoma Survivor, Shares Her Story" video](/_default_upload_bucket/1276/image-thumb__1276__width800/DDX%20Video%20Thumbnail.e4ff165c.png)
Be your own advocate: Morgan England, Stage III melanoma survivor, shares her story
As a Stage III Melanoma survivor, Morgan speaks on how important it is to be your own advocate. After her diagnosis, she requested the DecisionDx-Melanoma test from her doctor for the additional information it can provide. The results she received from her DecisionDx-Melanoma test report continue to help reduce her anxiety and provide confidence about her future.
![Click to play "DecisionDx-Melanoma Helps to Guide Patient Management Decisions" video](/_default_upload_bucket/568/image-thumb__568__width800/Aaron%20Farberg.a0ecdca5.png)
DecisionDx®-Melanoma Helps to Guide Patient Management Decisions
Dr. Aaron Farberg speaks about how the DecisionDx-Melanoma test results helps better identify a patient's risk of metastasis and how some patients may be able to forgo a SLNB procedure.
![Click to play "DecisionDx-Melanoma Increases the Risk Prediction that is Currently Available for Patients" video](/_default_upload_bucket/567/image-thumb__567__width800/Clay%20Cockerell.89933752.png)
DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients
Dr. Clay Cockerell speaks on how the DecisionDx-Melanoma test is not intended to replace staging systems but how using GEP can increase risk prediction for patients with Stage I-III melanoma.
![Click to play "Molecular Prognostic Tests are Changing Management of Dermatologic Cancer" video](/_default_upload_bucket/562/image-thumb__562__width800/Molecular%20Prognostic.f60ae842.png)
Molecular Prognostic Tests are Changing Management of Dermatologic Cancers
Learn more about how Gene Expression Profiling (GEP) can be used to individualize patient care and management of melanoma.
![Click to play "More Accurately Predicting Individual Risk of Recurrence or Metastasis" video](/_default_upload_bucket/561/image-thumb__561__width800/More%20Accurate.a796d45e.png)
More Accurately Predicting Individual Risk of Recurrence or Metastasis
DecisionDx- Melanoma can be used to determine what level of follow-up, imaging, and referrals are appropriate for individual patients.
![Click to play "SLNB Surgical Procedures: Improving Patient Selection" video](/_default_upload_bucket/560/image-thumb__560__width800/SLNB.837b56d9.png)
SLNB Surgical Procedures: Improving Patient Selection
DecisionDx-Melanoma can guide the decision of whether to perform or forgo a sentinel lymph node biopsy.
![Click to play "The Limitations of Traditional Approaches" video](/_default_upload_bucket/559/image-thumb__559__width800/Limitations.20d6e77f.png)
The Limitations of Traditional Approaches
Using staging systems alone may miss patients with aggressive tumor biology. Listen in, to learn how DecisionDx-Melanoma addresses these limitations by improving prognostic accuracy.